Randomized trial compares outcomes of olverembatinib plus immunotherapy with transplantation in adults with Ph+ ALL, suggesting effective consolidation strategies.
Philadelphia chromosome–positive (Ph⁺) acute lymphoblastic leukemia (ALL) accounts for approximately 20–30% of adult B-cell ALL cases [ 1 ]. Historically, Ph⁺ ALL has been associated with poor outcomes due to intrinsic chemoresistance. The integration of BCR::ABL1 tyrosine kinase inhibitors (TKIs) into frontline induction regimens has dramatically improved complete remission (CR) rates to >95%. Allogeneic hematopoietic cell transplantation (allo-HSCT) remains the standard consolidation strategy for patients in first CR [ 2 ].
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: